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Head and Neck Surgery
Cervical adenopathy in patients with squamous cell carcinoma 
(SCC) of the upper aerodigestive tract is assumed to represent 
nodal metastasis and is treated with therapeutic neck dissection. [1] 
Overstaging of the neck leads to overtreatment by modified 
neck dissection. In southern Africa and the developing world, 
the accuracy of clinical staging of cervical adenopathy in head 
and neck cancer may be confounded by the high prevalence of 
other causes of lymphadenopathy such as HIV, tuberculosis and 
untreated upper respiratory and dental infections. De Waal et al. 
reported a false-positive rate of 32% for the clinically node-positive 
(N+) neck when comparing clinical staging with pathological 
analysis in a study done in Cape Town.[2]
Sentinel lymph node biopsy (SLNB) has been employed for 
the node-negative (N0) neck to avoid unnecessary elective neck 
dissection (END).[1,3-6] However, no studies have been reported 
on the use of SLNB to distinguish between inflammatory and 
metastatic adenopathy in the clinically N+ neck as a means of 
avoiding unnecessary therapeutic neck dissection.
Aim of the study
The aim of the study was to determine whether SLNB can be used 
to reduce clinical overstaging of the cervical nodes in head and 
neck SCC in a developing world setting, and hence reduce the 
number of unnecessary comprehensive neck dissections done in 
clinically N+ but pathologically N0 necks.
Materials and methods
A cohort study of patients with T1-4 N0-3 SCC of the oral cavity 
and oropharynx undergoing primary resection and neck dissection 
was conducted at Groote Schuur Hospital, Cape Town, between 
March 2004 and May 2009. Tumours had to be accessible for 
transoral peritumoural injection. Pregnant and lactating patients 
were excluded, as were those who had undergone previous surgery 
or radiotherapy to the neck. SLNB findings did not alter the surgical 
management of the neck or the primary tumour. The study was 
approved by the University of Cape Town Ethics Committee.
Lymphoscintigraphy was done in the Department of Nuclear 
Medicine. Peritumoural injection of 99mTc-labelled human serum 
albumin (Nanocoll) was immediately followed by saline mouthwash 
to prevent pooling or swallowing of the residual radioactivity. 
Continuous-flow lymphoscintigraphy was performed for 30 minutes 
with a static film, 15 and 30 minutes after the injection. Sentinel 
lymph nodes (SLNs) detected on lymphoscintigraphy were marked 
on the skin using a radioactive tracer. In the operating theatre and 
after induction of general anaesthesia, 1 - 2 ml of methylene blue 
dye was injected into the mucosa and submucosa surrounding 
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the primary tumour. The neck was explored using standard neck 
dissection approaches. SLNs and echelon lymph nodes (ELNs) were 
identified using gamma probe localisation and by identifying blue-
stained lymphatics and lymph nodes. In some cases the primary 
tumour was removed before the neck was explored; this facilitated 
SLNB where shine-through of radioactivity from the primary 
tumour interfered with location of the SLN. The SLNs and ELNs 
were excised. Ex vivo radioactivity, colour and anatomical level 
of the nodes in the neck were recorded. Each node was sent for 
histological analysis in 10% formalin. Neck dissection and removal 
of the primary tumour were then completed.
Clinical details relating to tumour site, clinical stage, and 
levels of clinically palpable nodes were recorded. The numbers 
of radioactive-only nodes, blue-only nodes and nodes that were 
both radioactive and blue-stained, radiation counts of each 
node, background radioactivity and anatomical levels of the 
nodes were all documented. The time interval between isotope 
injection and surgery, the length of time for SLNB, the lymph 
node basins explored and any technical difficulties were also 
noted. Histopathological data recorded related to pathological 
stage (TNM), tumour thickness, status of the SLNs and nodal 
status of the rest of the neck dissection specimens.
Results
Thirty-three patients were available for analysis. The results 
are outlined in Table 1. The mean age was 58 years (range 
42 - 89 years), with a male/female ratio of 2.3:1. Both the 
N0 and N+ groups included T1-4 primary tumours; the N+ 
group comprised N1-3 patients. Three patients underwent 
lymphoscintigraphy the afternoon before surgery and the 
remainder immediately before surgery. The mean time interval 
between injection and surgery was 233 minutes (range 91 - 1 
185 minutes). The volume of peritumoural injection of 99mTc-
labelled human serum albumin varied with primary tumour 
size and ranged from 0.2 ml to 0.6 ml (mean 0.37 ml); the 
dosage was 29.0 - 66.0 MBq (mean 47.2 MBq).
The sensitivity and negative predictive value (NPV) of SLNB 
as predictor of N-stage of the lymph node basin were calculated 
separately for the N0 and N+ patient groups. The accuracy 
in detecting sentinel and echelon nodes in each group was 
determined for each individual diagnostic modality alone and 
for a combination of the modalities (Table 2). The N0 group 
comprised 13 patients, 12 of whom had undergone ipsilateral 
and 1 bilateral END (14 neck dissections). In the N+ group there 
were 20 patients, of whom 10 had undergone ipsilateral and 10 
bilateral modified radical neck dissections (30 neck dissections).
In the clinically N0 necks, combined lymphoscintigraphy, 
gamma probe and blue dye yielded sensitivity in identifying the 
sentinel nodes of 100% and an NPV of 100%. It follows that the 
methodology and technical expertise of lymphoscintigraphy and 
intra-operative identification of the SLNs were accurate and were 
not a confounding factor for the results achieved for N+ necks. 
In the clinically N+ group the sensitivities of the individual 
modalities to identify the 16 necks with metastases were 40% 
(scintigraphy), 67% (gamma probe) and 57% (blue dye), and the 
combined sensitivity and NPV for the three modalities used were 
71% and 60%, respectively.
Discussion
The principal reason for conducting our study was the concern 
that 32% of neck dissection specimens for clinically N+ necks 
in our unit were pathologically N0, and the patients had 
therefore been subjected to an unnecessary comprehensive neck 
dissection.[2] A theoretical problem of employing SLNB for the 
pathologically N+ neck is that when a lymph node contains 
metastatic carcinoma, lymphatic flow may be blocked in that 
lymphatic channel or node and the tracer or dye may be diverted 
past the true first echelon node(s) to a ‘false SN’.[7] The question 
therefore was whether SLNB in the N+ neck was sufficiently 
accurate to exclude cervical nodal metastases.
The reasoning behind SLNB is that the sentinel node is 
the first lymph node in a nodal basin that receives lymphatic 
drainage from a malignant tumour, and therefore theoretically 
is the first node to contain lymphatic metastasis; if a sentinel 
node is found to be free of metastatic disease, it can be inferred 
that the metastatic status of the remainder of the nodal 
basin will be negative. The lymphatic drainage of the breast 
and other regions of the body is relatively ordered.[7,8] SLNB 
using radioactive isotope, dye or combinations thereof is the 
standard of care in many centres for patients with N0 cutaneous 
malignant melanoma and breast carcinoma.[1] However, the 
drainage pathways in the head and neck are more complex and 
less predictable. Skip lesions may also occur, e.g. with SCC of the 
oral tongue and the floor of the mouth, which may ‘fast track’ to 
level IV, ‘bypassing’ levels I - III.[1,5,9,10] 
SLNB has a high degree of sensitivity, and is reliable and 
reproducible in N0 oral and oropharyngeal SCC.[1,4,11] Reported 
sensitivity ranges from 89% to 100%, with false-negative rates of 
0 - 12.5%.[1] In a meta-analysis of 19 studies, Paleri et al. reported 
an overall sensitivity of 0.926 (95% confidence interval 0.852 - 
0.964).[11] This concurs with the 100% sensitivity achieved for the 
clinically N0 group in our study. Despite the high sensitivity, to our 
knowledge there are no randomised controlled trials (RCTs) that 
compare SLNB with END in terms of patient outcome, rates of local 
recurrence or survival.[5] SLNB in head and neck SCC therefore 
remains a limited tool pending outcomes of RCTs.[1,5] There is also 
said to be a significant learning curve associated with SLNB, and it 
has been suggested that the technique be standardised.[5,11] It has also 
been suggested that its use should be restricted to early-stage (T1/2 
N0) SCC of the oral cavity and oropharynx.[5]
In the clinically N+ group, 4/20 patients were pathologically N0 
despite having clinically palpable lymph nodes; 20% of patients in 
this group had therefore undergone unnecessary neck dissections 
owing to the presumed clinical evidence of nodal metastases. 
The pre-operative clinical staging in these patients was T2N1, 
T3N1, T3N2b and T4N2c. Histologically the palpable nodes 
were generally reactive lymph nodes. Patients had not been 
routinely tested for HIV and there was no histological evidence of 
tuberculosis.
The sensitivities of scintigraphy (40%), gamma probe (67%), 
blue dye (57%) and the combination of the three techniques 
(71%) to accurately stage the necks in terms of nodal metastases 
in the clinically N+ group were inadequate to direct surgeons on 
whether to proceed to comprehensive neck dissection. Our results 
in clinically N0 necks indicate that the poor accuracy of SLNB in 
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these necks was not due to technical issues or a ‘learning curve’ 
associated with the procedure, but reflects inadequacy of SLNB as 
a staging tool in the clinically N+ neck.
Conclusions
Despite confounding causes responsible for cervical lympha-
denopathy in the developing world setting, SLNB cannot be relied 
upon to direct the therapeutic approach in the clinically N+ neck 
in patients with mucosal SCC of the head and neck.
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Table 1. Results of the sentinel node biopsy study
Patient 
number Tumour site




Sentinel nodes Non-sentinel nodes
T N L R L R
1 Tongue ant. 2/3, FOM, inferior alveolus R 4 0 N N
2 Tongue ant. 2/3 L 1 0 N N
3 Tongue ant. 2/3, FOM L 2 0 Y N
4 Tongue ant. 2/3 L 3 0 N N
5 Buccal, retromolar trigone L 4 0 N N
6 Tongue post. 1/3 L 2 0 N N
7 Tongue post. 1/3 L 2 0 N N
8 Buccal, inferior alveolus L 4 0 Y Y
9 FOM L/ML 3 0 N N N N
10 FOM, buccal & inferior alveolus R 4 0 N N
11 Tongue post. 1/3, buccal R 2 0 N N
12 Tongue ant. 2/3 L 3 0 Y N
13 Buccal, inferior alveolus R 4 0 N N
14 FOM L 2 1 Y N
15 FOM R 2 1 N N N N
16 Tongue R 4 2b Y Y
17 Tongue ant. 2/3, post. 1/3 L 3 2a Y Y
18 FOM L 1 3 Y N Y N
19 FOM L/ML 4 2c N N Y Y
20 FOM, inferior alveolus R/ML 4 2c N N N N
21 Tongue ant. 2/3 and post. 1/3 L 3 1 N Y
22 Tongue post. 1/3, soft palate R 3 2a N Y
23 Tongue ant. 2/3, post. 1/3, hard and soft palate L 4 2a Y Y
24 FOM L/ML 2 2b N N Y N
25 Tongue ant. 2/3 L 3 1 Y Y
26 FOM L/R 3 2c N Y Y N
27 Tongue post.1/3, retromolar trigone, soft palate L 3 2b Y N
28 FOM/inferior alveolus L/R 4 2c N Y N N
29 Tongue post. 1/3 R 3 1 N N
30 Buccal mucosa R 3 2b N N
31 Tongue ant. 2/3 R 3 2c Y Y N Y
32 FOM L/R 3 2c Y N N N
33 Tongue post. 1/3, ant. 2/3 L/R 3 2c Y Y Y Y
SCC = squamous cell carcinoma; sentinel nodes = sentinel lymph nodes including echelon nodes; non-SN nodes = all other lymph nodes in the neck dissection specimens; 
FOM = floor of mouth; T = tumour; N = node; L = left; R = right; ML = midline; ant. = anterior; post. = posterior; Y = positive for SCC; N = negative for SCC.
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Table 2. Accuracy of sentinel lymph node biopsy in detecting nodal metastases
Combined modalities Scintigraphy Gamma probe Blue dye
Clinically N0 group
Sensitivity, % 100 100 100 100
NPV, % 100 100 100 100
Clinically N+ group
Sensitivity, % 71 40 67 57
NPV, % 60 46 56 50
Combined modalities = sentinel and echelon nodes determined by all three modalities; N0 = node negative; N+ = node positive; NPV = negative predictive value.
